Japan Rewrites Its Cannabis Law After 75 Years

Photo by Cheng via Pexels.

For 75 years, Japan's Cannabis Control Act sat on the books largely untouched, a piece of Allied occupation-era legislation that nobody in the Diet bothered to revisit in any structural way. That changed on December 6, 2023, when lawmakers passed a sweeping set of amendments that rewired how the country treats marijuana, both as a criminal matter and, in a narrower sense, as a potential medicine.

The old statute had a strange gap in it. It banned possession, cultivation, and sale of cannabis, but it never actually made use of the drug itself a crime. That meant a positive drug test alone couldn't put someone in legal jeopardy the way it could with methamphetamine or other narcotics -- a quirk regulators and legal scholars had long called an anomaly, and one that became harder to defend as youth cannabis cases climbed.

The major provisions of the 2023 amendments, including the new criminalization of use, took effect on December 12, 2024, folding cannabis regulation into Japan's existing narcotics control framework for the first time. What follows is a look at how that loophole persisted for so long, why Tokyo finally acted, how enforcement has already shifted on the ground, and what the changes mean for medical research and the country's CBD industry, which is now waiting nervously on a separate rulemaking process that could reshape it entirely.

The Loophole That Existed for 75 Years

Photo by Christian Wasserfallen via Pexels.

Japan's Cannabis Control Act was drafted in 1948, during the Allied occupation, at a time when the country's drug policy apparatus was being rebuilt almost from scratch under American oversight. It criminalized possession, cultivation, and transfer of cannabis with real teeth, but it left one thing conspicuously out: there was no clause punishing the act of using cannabis itself. Legally speaking, a person could test positive for THC metabolites and still walk away without a chargeable offense, so long as investigators couldn't also prove they had physically possessed the drug at some point.

That gap wasn't an oversight so much as a fossil -- a structural choice from 1948 that nobody had bothered to correct through 75 years of otherwise active drug policy in Japan. Stimulants, opioids, and other narcotics under Japan's parallel Narcotics and Psychotropics Control Act carried no such exemption; a positive test for methamphetamine, for instance, has long been sufficient grounds for prosecution on its own. Cannabis stood apart, and legal scholars periodically flagged the inconsistency as difficult to justify on public health or enforcement logic.

The Ministry of Health, Labour and Welfare took up the question formally in 2021, convening an expert panel to review the Cannabis Control Act's adequacy against modern drug enforcement standards and international testing norms. That panel's work built on Diet committee reviews that ran from 2020 through 2023, a slow-moving process typical of Japanese legislative reform, where consensus-building across ministries and party factions tends to precede any actual bill. The eventual amendments didn't emerge from a sudden policy reversal -- they were the product of several years of bureaucratic groundwork finally catching up to a loophole everyone involved had already identified.

What the December 2023 Amendment Actually Did

Photo by KATRIN BOLOVTSOVA via Pexels.

On December 6, 2023, Japan's Diet passed comprehensive amendments touching both the Cannabis Control Act and the Narcotics and Psychotropics Control Act, and the restructuring went further than simply adding a use-prohibition clause. Cannabis and THC were reclassified as narcotics under the narcotics control law, pulling them out of their standalone legal category and placing them alongside methamphetamine, opioids, and other controlled substances for the first time since Japan began regulating drugs in the postwar period.

The penalty structure shifted too. Maximum sentences for possession, transfer, and now use were raised to seven years, up from the previous five-year ceiling, bringing cannabis offenses closer in severity to how Japan treats other narcotics violations. That increase reflects the reclassification itself: once cannabis sits within the narcotics framework rather than its own separate statute, its penalty scale tends to track more closely with substances Japan has historically prosecuted harshly.

Rather than repeal the original 1948 law outright, legislators renamed it the Law on Cannabis Cultivation Regulation, stripping it down to a much narrower function -- licensing and overseeing cannabis cultivation, particularly for industrial hemp and, going forward, pharmaceutical-grade production. It's an unusual bit of legislative housekeeping: the old law didn't disappear, it got demoted to a regulatory instrument for growers, while the criminal provisions migrated entirely into the narcotics control law.

The timeline matters here too. While the amendments passed in December 2023, the major provisions -- including the criminalization of use -- didn't actually take effect until December 12, 2024, giving ministries and police a full year to prepare enforcement guidance, update training, and align testing protocols with the new statute before it became operative.

Why Tokyo Moved Now: A Record Year for Offenses

Legislative reform in Japan rarely moves on its own momentum, and this one had a fairly stark trigger: Japan logged a record 6,703 cannabis-related offenses in 2023, according to National Police Agency figures, marking the first time on record that cannabis cases outnumbered methamphetamine cases in a given year. For a country where methamphetamine has historically been the dominant illicit drug problem by a wide margin, that crossover was treated as a genuine inflection point inside the ministries reviewing the law.

What made the numbers more alarming to officials wasn't just the total, but who was showing up in them. Kyodo News reported that more than 70% of those investigated in cannabis cases were teenagers or people in their 20s, a demographic skew that stood out against typical patterns for other narcotics offenses in Japan, which tend to involve older offenders. That youth concentration gave the reform effort a practical urgency that years of academic and legal-scholar critique of the 1948 loophole hadn't managed to generate on its own.

Officials pointed directly to the rising youth-use trend as the practical catalyst that finally pushed years of MHLW panel work and Diet committee review into an actual bill. The loophole had been an acknowledged oddity since well before 2020, but oddities rarely produce legislation by themselves -- a record year of offenses, concentrated among young people, gave lawmakers the political cover and public health justification to act.

There's also a quieter administrative logic at work. Japan's shift brings its statute books in line with how cannabis is actually tested and prosecuted in most other jurisdictions with strict drug laws, where metabolite testing alone has long been standard grounds for prosecution. Japan's old system, by contrast, had been an outlier -- one where enforcement depended on catching someone with the substance in hand rather than in their bloodstream.

How Enforcement Changed on the Ground

Photo by cottonbro studio via Pexels.

Before December 2024, Japanese police enforcement around cannabis had a hard practical limit: only physical possession could trigger an arrest and detention. An officer could have a urine test come back positive for THC metabolites, but if the person's pockets, bag, and residence were clean of any actual cannabis, there was no chargeable offense to pursue. That created real operational friction for police, who could identify use through testing but had no legal hook to act on it.

The amended law closes that gap directly. Urine, blood, or hair samples showing cannabis metabolites are now sufficient grounds for prosecution on their own, with no requirement to also establish possession at the time of testing or arrest. That's a fundamental shift in the evidentiary bar, and it puts cannabis enforcement on the same footing as how Japan has handled methamphetamine cases for decades, where a positive test has long been enough to build a case.

The new provision didn't stay theoretical for long. Tokyo police made the first arrests under the use-prohibition on March 31, 2025, less than four months after it took effect, detaining two individuals after urine tests confirmed the presence of cannabis metabolites. There was no possession charge attached -- the test results themselves were the basis for detention, exactly the scenario the old law couldn't touch.

The practical implication is significant, and it extends beyond Japanese residents. Travelers and foreign nationals accustomed to jurisdictions where possession is the operative threshold need to recalibrate their assumptions about risk in Japan. Consumption abroad, if it shows up in a test administered after arrival, is no longer legally irrelevant the way it effectively was under the pre-2024 framework. Anyone with cannabis metabolites still detectable in their system when entering Japanese jurisdiction is now operating under meaningfully different legal exposure than before.

A Narrow Opening for Medical Cannabis

Photo by Jonathan Borba via Pexels.

Buried inside the same 2023 amendment package was a change that runs in the opposite direction of the tightened criminal enforcement: Japan lifted its long-standing blanket ban on pharmaceuticals containing marijuana-derived ingredients. Previously, Japan's drug laws made no allowance whatsoever for cannabis-based medicine, regardless of formulation or clinical evidence, putting the country well behind peers that had already approved cannabinoid-based treatments for epilepsy and other conditions.

Under the revised framework, cannabis-derived drugs can now be approved through the same regulatory pathway used for morphine and other controlled medicines, provided efficacy and safety are established through Japan's standard pharmaceutical review process. That's a meaningful structural opening, even if it's a cautious one -- it puts cannabis-based medicine on a track that already exists rather than carving out special new machinery, which should, in theory, streamline eventual approvals.

As of mid-2026, though, no cannabis-derived pharmaceutical product has actually cleared that process for the Japanese market. The legal door is open, but nothing has walked through it yet, which says something about how conservatively Japan's pharmaceutical regulators are likely to treat the first applications in this category.

The cultivation side of the law got restructured too. The renamed cultivation-regulation statute now establishes two license tiers: a Type 1 license for industrial cannabis cultivation, covering hemp fiber, seed, and similar non-pharmaceutical uses, and a Type 2 license specifically for pharmaceutical-grade cultivation intended to feed future drug development. The health ministry has said it intends to overhaul the broader cultivation licensing system by the end of 2025, a deadline that will determine how quickly domestic growers can actually begin supplying material for the pharmaceutical pathway the amendment just created.

The CBD Industry's Anxious Wait

Photo by Oliver King via Pexels.

Japan's CBD market had grown into a genuinely sizable business well before any of this legislation passed, valued at roughly ¥25 billion -- around $160 million -- in 2023, built almost entirely on imported hemp extracts rather than domestic cultivation. That market now sits in a holding pattern, waiting on a rulemaking process tied to the same cultivation overhaul mentioned above, and the stakes for existing retailers are considerable.

The sticking point is THC residual limits. Regulators have proposed thresholds as strict as 0.001% for CBD products sold in Japan, a figure far tighter than the limits common in markets like the U.S. or EU, where thresholds in the range of 0.2% to 0.3% are typical. Industry estimates suggest more than 90% of CBD products currently sold in Japan would fail to meet a 0.001% standard, which would functionally wipe out most of the existing product catalog overnight if adopted as written.

Retailers and importers have been actively lobbying the health ministry for a workable middle ground as the rulemaking proceeds alongside the broader cultivation license overhaul. Their argument, in essence, is that a threshold this strict doesn't track any real public health risk -- trace THC at 0.001% is not remotely psychoactive -- and instead functions as a de facto ban dressed up as a purity standard.

How this resolves will determine the shape of Japan's legal CBD sector for years to come. A final rule anywhere near the proposed 0.001% figure would force a sharp contraction, pushing most current products off shelves and likely consolidating the market around a handful of manufacturers capable of producing verifiably ultra-low-THC extracts. A looser final standard, closer to international norms, would let the existing industry largely adapt in place. Either way, this is the piece of Japan's cannabis overhaul still genuinely undecided, and it's the one with the most immediate commercial consequences.

It's worth being precise about what actually happened here, because it cuts against the general global drift toward cannabis liberalization. Japan didn't loosen its stance on cannabis -- it tightened it, closing a 75-year-old technicality that had let use go unprosecuted even as possession carried real criminal weight. The narrative of "Japan reforms cannabis law" obscures more than it reveals if it implies relaxation; what actually happened is that enforcement got sharper and penalties got heavier, even as a narrow, separate door opened for pharmaceutical research.

The unresolved question sits with the CBD industry, not the criminal law. The rulemaking around THC residual thresholds -- potentially as strict as 0.001% -- is still underway, and its outcome will decide whether Japan's roughly $160 million legal CBD sector survives in something like its current form or gets gutted by a purity standard that industry estimates say more than 90% of existing products can't meet. That's the piece worth watching closely over the next year, since the health ministry has tied it to the broader cultivation licensing overhaul it's aiming to finish by the end of 2025.

For anyone visiting or living in Japan, the practical takeaway is straightforward and worth internalizing: testing alone, not just possession, can now trigger prosecution under the revised framework. The first arrests under the new use-prohibition came within months of the law taking effect, and there's no reason to expect enforcement to stay cautious or symbolic. The legal ground shifted in December 2024, and the assumptions travelers and residents carried under the old law no longer apply.